Edgewise Therapeutics (NASDAQ:EWTX - Get Free Report) had its price objective hoisted by research analysts at JPMorgan Chase & Co. from $60.00 to $69.00 in a note issued to investors on Friday, Benzinga reports. The firm currently has an "overweight" rating on the stock. JPMorgan Chase & Co.'s target price indicates a potential upside of 71.96% from the stock's current price.
A number of other equities research analysts have also issued reports on the stock. HC Wainwright restated a "buy" rating on shares of Edgewise Therapeutics in a research note on Wednesday, October 14th. Weiss Ratings restated a "sell (d-)" rating on shares of Edgewise Therapeutics in a research note on Thursday, October 15th. The Goldman Sachs Group increased their target price on Edgewise Therapeutics from $32.00 to $36.00 and gave the stock a "neutral" rating in a report on Tuesday, August 11th. William Blair started coverage on Edgewise Therapeutics in a research report on Friday, October 16th. They issued an "outperform" rating for the company. Finally, Wall Street Zen upgraded Edgewise Therapeutics from a "sell" rating to a "hold" rating in a report on Sunday, October 4th. Nine investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, Edgewise Therapeutics presently has a consensus rating of "Moderate Buy" and an average price target of $53.58.
Read Our Latest Report on Edgewise Therapeutics
Edgewise Therapeutics Trading Down 2.5%
EWTX stock traded down $1.04 on Friday, hitting $40.12. The company's stock had a trading volume of 255,591 shares, compared to its average volume of 1,285,375. Edgewise Therapeutics has a 1 year low of $19.76 and a 1 year high of $48.78. The firm has a 50 day moving average of $41.23 and a two-hundred day moving average of $37.26. The stock has a market cap of $4.39 billion, a price-to-earnings ratio of 4.92 and a beta of 0.39.
Edgewise Therapeutics (NASDAQ:EWTX - Get Free Report) last released its earnings results on Wednesday, November 4th. The company reported $9.65 EPS for the quarter, beating analysts' consensus estimates of ($0.53) by $10.18. As a group, equities analysts forecast that Edgewise Therapeutics will post 9.11 EPS for the current fiscal year.
Insiders Place Their Bets
In other news, CMO Joanne M. Donovan sold 854 shares of the stock in a transaction dated Monday, November 16th. The stock was sold at an average price of $45.48, for a total transaction of $38,839.92. Following the transaction, the chief marketing officer owned 8,139 shares of the company's stock, valued at approximately $370,161.72. This represents a 9.50% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Michael Nofi sold 4,442 shares of Edgewise Therapeutics stock in a transaction that occurred on Tuesday, November 10th. The shares were sold at an average price of $45.43, for a total transaction of $201,800.06. Following the completion of the transaction, the chief financial officer directly owned 6,495 shares in the company, valued at approximately $295,067.85. This represents a 40.61% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Corporate insiders own 21.30% of the company's stock.
Hedge Funds Weigh In On Edgewise Therapeutics
Hedge funds have recently made changes to their positions in the business. BlackRock Inc. bought a new stake in shares of Edgewise Therapeutics in the 2nd quarter worth about $268,415,000. Jupiter Topco LLC acquired a new position in Edgewise Therapeutics during the 2nd quarter worth about $246,945,000. Janus Henderson Group PLC increased its position in Edgewise Therapeutics by 29.5% in the 1st quarter. Janus Henderson Group PLC now owns 5,915,556 shares of the company's stock valued at $186,289,000 after acquiring an additional 1,348,706 shares in the last quarter. Bank of America Corp DE bought a new stake in shares of Edgewise Therapeutics during the second quarter valued at approximately $63,312,000. Finally, Marshall Wace LLP increased its holdings in shares of Edgewise Therapeutics by 20,477.5% in the third quarter. Marshall Wace LLP now owns 1,255,226 shares of the company's stock valued at $50,962,000 after purchasing an additional 1,249,126 shares in the last quarter.
About Edgewise Therapeutics
(
Get Free Report)
Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for serious muscle disorders. Founded in 2017 and based in Boulder, Colorado, the company researches small-molecule treatments designed to address the underlying biology of muscle and cardiac conditions. Its programs include sevasemten, an investigational therapy for Duchenne and Becker muscular dystrophies, and EDG-7500, an investigational treatment being developed for hypertrophic cardiomyopathy.
Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Edgewise Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Edgewise Therapeutics wasn't on the list.
While Edgewise Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.